Jyh-Haur Chern, Ph.D.
Institute of Biotechnology and Pharmaceutical Research
EDUCATIONPh.D., Organic Synthesis, National Chiao Tung University, Hsinchu, Taiwan (1997)
B.Sc., Chemistry, Tamkang University, Taipei, Taiwan (1989)
PROFESSIONAL EXPERIENCESAssociate Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2006-present)
Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2002-2006)
Research Associate, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2000-2002)
Postdoctoral Fellow, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (1998-2000)
Postdoctoral Fellow, Institute of Chemistry, Academia Sinica, Taiwan (1997-1998)
RESEARCH INTERESTSDr. Chern’s research interests are in the areas of drug discovery and development of anti-EV71 and anti-HCV agents. His laboratory has been found two classes of novel EV71 inhibitors. It’s very interesting to note that the imidazolidinone DBPR103 was identified as an orally bioavailable antiviral compound with potent activity against EV71. Dr. Chern’s current work is focused onto the rational drug design andsynthesis of new hepatitis C virus NS3/4A protease inhibitors.
RESEARCH ACTIVITIES & ACCOMPLISHMENTSDr. Chern’s major is in medicinal chemistry and synthetic chemistry. Over these years, he participated in the projects on drug discovery of antienterovirus and anti-HCV, particularly on the project to target VP-1 by anti-EV71 compounds. His team successfully receives 4 US patents and 2 ROC patents for the antienterovirus study; and currently one pending patents. Dr. Chern published 9 papers in solid journals including JMC and BMCL in the area of medicinal chemistry. His participation in the anti-HCV projects has also yielded in discovering lead compounds targeting at NS3 protease, and one US patent application for the anti-HCV study has been filed recently.
SELECTED PUBLICATIONS1.Chen TC, Liu SC, Huang PN, Chang HY, Chern JH* and Shih SR*. Antiviral activity of pyridyl imidazolidinones against enterovirus 71 variants. J. Biomed. Sci., 2007, accepted.
2.Chern JH, Chang CS, Tai CL, Lee YC, Lee CC, Kang IJ, Lin YT, Lee CY and Shih SR. Synthesis and Antipicornavirus Activity of (R)-and(S)-1-[5-(4’-Chlorobiphenyl-4-yloxy)-3-methylpentyl]-3-pyridin-4-yl-imidazolidin-2-one. Bioorg. Med. Chem. Lett., 15(19): 4206-4211, 2005.
3.Chang CS, Lin YT, Shih SR, Lee CC, Lee YC, Tai CL, Tseng SN and Chern JH. Design, Synthesis, and Antipicornavirus Activity of 1-[5-(4-Arylphenoxy)alkyl]-3-pyridin-4-yl-imidazolidin-2-one Derivatives. J. Med. Chem., 48:3522-3535, 2005.
4.Chern JH, Chen CC and Shih SR. DBPR-103: A Novel Anti-EV 71 Compound. SCBA/BioPharm., 10 (3): 9-13, 2004.
5.Chern JH, Lee CC, Chang CS, Lee YC, Tai CL, Lin YT, Shia KS, Lee CY and Shih SR. Synthesis and Antienteroviral Activity of a Series of Novel, Oxime Ether-Containing Pyridyl Imidazolidinones. Bioorg. Med. Chem. Lett., 14 (20):5051-5056, 2004.
6.Chern JH, Shia KS, Hsu TA, Tai CL, Lee CC, Lee YC, Chang CS, Tseng SN and Shih SR. Design, Synthesis, and Structure-Activity Relationship of Pyrazolo[3,4-d]pyrimidines: A Novel Class of Potent Enterovirus Inhibitors. Bioorg. Med. Chem. Lett., 14(10):2519-2525, 2004.
7.Chern JH, Shia KS, Chang CM, Lee CC, Lee YC, Tai CL, Lin YT, Chang CS and Tseng HY. Synthesis and In Vitro Cytotoxicity of 5-Substituted 2-Cyanoimino-4-imidazodinone and 2-Cyanoimino-4-pyrimidinone Derivatives. Bioorg. Med. Chem. Lett., 14(5):1169-1172, 2004.
8.Shia KS, Li WT, Chang CM, Hsu MC, Chern JH, Leong MK, Tseng SN, Lee CC, Lee YC, Chen SJ, Peng KC, Tseng HY, Chang YL, Tai CL and Shih SR. Design, Synthesis, and Structure-Activity Relationship of Imidazolidinone Derivatives: A Novel Class of Potent and Selective Human Enterovirus 71 Inhibitors. J. Med. Chem., 45: 1644-1655, 2002.
PATENTUS Patent No. 6706739 B2 “Imidazolidinone Compounds”; granted 2002.
US Patent No. 6815444 B2 “Anti-enterovirus Compounds”; granted 2003.
US Patent No. 20040116476 A1 “Imidazolidinone Compounds”; granted 2003.
US Patent Pending No. 20050267164 A1 “Imidazolidinoe Compounds”; pending 2004.